Kyntra Bio presents roxadustat-focused strategy after ending FG-3246 program
KYNB•Kyntra Bio ended its FG-3246 and FG-3180 programs after insufficient efficacy in a planned Phase 2 interim analysis, shifting resources to roxadustat for anemia in lower-risk MDS. The company expects to start Phase 3 in the first quarter of 2027, contingent on a partnership or external financing, and says its cash runway should extend into 2028.
1. Program changes
Kyntra Bio terminated FG-3246 and FG-3180 in the fourth quarter of 2026 after insufficient efficacy in a planned Phase 2 interim analysis. Returning FG-3246 rights to Fortis Therapeutics is expected to reduce operating expenses by more than $20 million in 2027 and 2028.
2. Roxadustat and financing
The company is shifting resources to roxadustat for anemia in lower-risk MDS, with Phase 3 initiation expected in the first quarter of 2027, contingent on a partnership or external financing. A royalty restructuring cut maximum aggregate payment obligations by $60 million, leaving $15 million in future royalty-backed payments; Kyntra Bio expects its cash runway to extend into 2028.




